Coltuximab ravtansine (SAR3419) is an antibody-drug conjugate (ADC) targeting CD19 created by conjugating a derivative of the potent microtubule-acting cytotoxic agent, maytansine, to a version of the anti-CD19 antibody, anti-B4, that was humanized as an IgG1 by variable domain resurfacing. Four different linker-maytansinoid constructs were synthesized (average ∼3.5 maytansinoids/antibody for each) to evaluate the impact of linker-payload design on the activity of the maytansinoid-ADCs targeting CD19. Anti-CD19 humanized monoclonal antibody conjugated to DM4.

CSDHD10801

Chimeric

Human

Liquid

PBS buffer pH 7.5

1mg/ml

>95%

Monoclonal

IgG1-kappa

Research Grade Coltuximab Biosimilar

CD19,Differentiation antigen CD19,T-cell surface antigen Leu-12,B-lymphocyte antigen CD19,B-lymphocyte surface antigen B4

Protein A or G purified from cell culture supernatant.

Please contact with the lab for this information.

Mammalian cells

P15391

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

SDS PAGE for Coltuximab Ravtansine

For research use only .